Boehringer Ingelheim has bought a preclinical oncology asset from long-time collaborator OSE Immunotherapeutics, in addition to expanding the scope of two existing clinical programs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,